Nafoxidine: Difference between revisions
Content deleted Content added
No edit summary |
|||
| Line 26: | Line 26: | ||
== External links== |
== External links== |
||
*[http://www.sciscoop.com/story/2005/10/21/142936/01 Lednicer writes a few pages about his career as a chemist and his time at Upjohn] |
|||
* [http://openwetware.org/wiki/Tamoxifen Tamoxifen on OpenWetWare], a life scientist wiki |
|||
{{Sex hormones}} |
{{Sex hormones}} |
||
Revision as of 07:28, 11 August 2009
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.222.756 |
| Chemical and physical data | |
| Formula | C28H31NO2 |
| Molar mass | 425.562 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Nafoxidine is a non-steroidal antiestrogenic drug that has been investigated to treat advanced breast cancer.[1] It is structurally related to tamoxifen.
The drug is one of a series of similar structures invented by Dan Lednicer at Upjohn in 1961.[2]
US Patents
- U.S. patent 3,274,213 September 1966 Lednicer
- U.S. patent 3,293,263 December 1966 Lednicer
- U.S. patent 3,313,853 April 1967 Lednicer
- U.S. patent 3,320,271 May 1967 Lednicer
- U.S. patent 3,396,169 August 1968 Lednicer
- U.S. patent 3,567,737 March 1971 Lednicer
- U.S. patent 3,862,232 January 1975 Lednicer
References
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1002/mpo.2950040207, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1002/mpo.2950040207instead. - ^ U.S. patent 3,274,213
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |